isosorbide-hydralazine combination (BiDil)

10/02/2014 - "The African American Heart Failure Trial (A-HeFT) and the FDA approval of BiDil for race-specific prescription have stirred the debate about the scientific and medical status of race. "
01/01/2003 - "The claim that blacks die from heart failure at a rate twice that of whites is informing efforts to develop and market the drug BiDil, which is currently undergoing clinical trials to be approved by the FDA as the first drug ever specified to treat African Americans--and only African Americans--for heart failure. "
09/01/2013 - "BiDil was approved specifically as a secondary treatment for heart failure in African-American patients. "
04/01/2011 - "This was the rationale for the FDA approval of BiDil for treatment of heart failure in African Americans. "
03/01/2010 - "Recent clinical guidelines advocate the use of the isosorbide dinitrate/hydralazine combination in treatment for heart failure. "

01/01/2008 - "In contrast to discussions of BiDil, this paper explores racial meaning-making processes around an old generic hypertension drug. "